Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Regulatory solute carrier protein family 1 member 1 (RSC1A1)
- Target
- RSC1A1
- Molecular classification
- Other (regulatory protein), Transcriptional regulator, Transporter regulator
01
Overview
Regulatory solute carrier protein family 1 member 1 (RSC1A1) is a regulatory protein that modulates the expression and membrane localization of key solute carriers, primarily the sodium/glucose cotransporter SLC5A1 and the organic cation transporter SLC22A2. It exerts its action through transcriptional and post-transcriptional mechanisms, including inhibition of transporter protein exocytosis via a dynamin and PKC-dependent pathway and regulation of vesicle trafficking from the trans-Golgi network. The protein may be found in the trans-Golgi network or in the nucleus depending on the cell cycle stage, and is implicated in glucose-dependent short-term inhibition of transporter activity. Disease associations include lysosomal mannosidosis, though direct roles in common therapeutic indications are not well-established
- Other names
- hRS1RS1Transporter regulator RS1RSC1A1regulatory solute carrier protein, family 1, member 1
02
Mechanism of action
Transcriptional and post-transcriptional inhibition of SLC5A1 and SLC22A2, inhibition of dynamin/PKC-dependent exocytosis, regulation of vesicle release from trans-Golgi network
03
Biological functions
Regulation of sodium/glucose cotransporter SLC5A1 expression and activityRegulation of organic cation transporter SLC22A2 expressionNegative regulation of D-glucose transmembrane transportInhibition of exocytosis of SLC5A1 proteinPossible short-term glucose-dependent regulation of transporter activity
04
Disease associations
Mannosidosis, beta A, lysosomalno widely established roles in cancer or inflammation have been confirmed
05
Safety considerations
Not characterized; as RSC1A1 regulates solute carrier proteins, off-target modulation could disrupt glucose or organic cation homeostasis, but therapeutic safety data is not available
06
Interacting drugs
None directly documented; modulation of transporter activities (SLC5A1, SLC22A2) may indirectly affect drug transport, but no direct pharmacological modulators of RSC1A1 are reported in current literature
07
Biomarkers
None established for patient selection or efficacy monitoring; potential biomarker value in transporter-related pathologies not reported
Beyond the preview
Go deeper on Regulatory solute carrier protein family 1 member 1 (RSC1A1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Regulatory solute carrier protein family 1 member 1 (RSC1A1).